We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.40 | 0.20% | 1,708.60 | 1,708.60 | 1,708.80 | 1,713.00 | 1,699.40 | 1,701.60 | 11,522,668 | 16:29:59 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.27 | 70.34B |
Date | Subject | Author | Discuss |
---|---|---|---|
30/1/2019 13:31 | Sector rotation starting to take place. The pharmas should have a good run for a while. GSK and AZN powering ahead. | fuji99 | |
30/1/2019 12:42 | If there is any CGT payable as a result of presumed sale, that represents value destruction. A demerger has been intimated but debt is debt. New drugs are the solution. | zicopele | |
30/1/2019 11:57 | Presumably they believe that a breakup would be by a sale, rather than a share distribution. The proceeds used to pay off debt. | alphorn | |
30/1/2019 11:53 | How is a breakup a solution to debt? Debt has to be repaid. Solution to debt is drug discoveries and that may include reducing dividend. Hopefully Tesaro will be successful as acquisition. | zicopele | |
30/1/2019 09:13 | Tipped by Telegraph: Questor: "Glaxo’s breakup is a neat solution to its debt problem, so it’s time to buy back in" | tradermichael | |
30/1/2019 08:49 | Fantastic, they said 1 in 3 people will get shingles, massive market. I paid 130 pounds for a shingles vac.GSK double blockbuster on Shringlix I reckon. | montyhedge | |
30/1/2019 08:38 | Glaxo has seen strong growth momentum in its three new products — Trelegy Ellipta, Shingrix and Juluca – so far this year - each could become a blockbuster | tradermichael | |
30/1/2019 08:32 | Demand outstripping supply for shingles vac, what a great problem to have. Already blockbuster could we have double blockbuster coming years for that vaccine. | montyhedge | |
29/1/2019 18:00 | Yes lessons were learnt,good bittersweet memories,no regrets easy come easy go,that's life! | abdullla | |
29/1/2019 16:41 | Same here....I paid for a holiday on a company called eprime financial. Lost on scoot.com and Marconi. Remember John Mayo? | zicopele | |
29/1/2019 16:39 | Yeah, I made and lost a fortune on Scoot. | tradermichael | |
29/1/2019 16:21 | Crikey...Energis is a name from the past. Anyone remember the shill who used to shamelessly pump Sopheon? Those companies went pop in 2001. Scoot.com.is another beauty. | zicopele | |
29/1/2019 16:04 | Abdullla woz with TMF in the late sixties,these were the times of the disgraced Baltimore,Marconi and Energis all now are RIP! | abdullla | |
29/1/2019 15:40 | Long since given up with TMF Their articles are anodyne and generic - its a shame as back in the early days they used to offer some insight and the tips actually did quite well. I did have a few conversations with one of the better authors too. | dr biotech | |
29/1/2019 14:56 | Stupid article - the GSK network of local subsidiaries will ensure minimal impact of any loss of sales on the Continent for currently approved products. | alphorn | |
29/1/2019 13:59 | TMF is run by shysters. One says buy on a share and his colleague advises sell. | zicopele | |
29/1/2019 13:17 | A couple of snippets from TMF: See the recent relation of the share price to results announcements. The price has fallen between 1% and 3.5% on three of the previous four results days in the past year, but has recovered quickly thereafter. As far as Brexit,less than 30% of the companies’ revenues came from Europe in the last quarter, with the rest coming from the US and other international markets, helping to protect it from excessive exposure to a possibly-weaker UK or EU economy. | tradermichael | |
29/1/2019 12:59 | Our next quarterly dividend soon is 23p, dividend on the doormat every 13 weeks, I love GSK, lol. | montyhedge | |
29/1/2019 12:54 | Forward guidance not good. | zicopele | |
29/1/2019 12:52 | They beat on earnings, beat on sales, investors always want more, lol. | montyhedge | |
29/1/2019 12:50 | PFE is down in the premarket | zicopele | |
29/1/2019 11:49 | Good figures and they beat analyst forecasts, just out from Pfzier bodes well for the sector. | montyhedge | |
29/1/2019 09:05 | There will probably be a sector rotation and IMO the bio/pharmas turn has arrived as they lost a lot in just less than 2 weeks - Reference to GSK and AZN in particular. This is following a strong run by oilers and miners in particular. Defensive stocks will follow for a nice run. | fuji99 | |
29/1/2019 08:50 | Nice problem to have demand far outweighed supply. | montyhedge |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions